Filing summary
Entity note: The supplied filing is Vital Therapies, Inc.’s Form 10-Q, not an Immunic, Inc. filing. It covers the quarter ended June 30, 2017, and was signed August 3, 2017. Financial statements are unaudited.
Business context and reporting period
Vital Therapies is a clinical-stage biotherapeutics company developing ELAD, an extracorporeal cell-based therapy for acute liver failure. It has no product revenue and depends on ELAD, its sole product candidate. Its Phase 3 VTL-308 trial is evaluating ELAD in severe alcoholic hepatitis (sAH), following the failure of the prior VTI-208 Phase 3 trial to meet its primary and secondary endpoints.
Key financial metrics
| Metric | Three months ended June 30, 2017 | Six months ended June 30, 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $9.8 million | $19.5 million |
| General and administrative expense | $2.7 million | $5.8 million |
| Total operating expenses | $12.5 million | $25.2 million |
| Net loss | $12.4 million | $25.0 million |
| Net loss per share, basic and diluted | $0.29 | $0.67 |
Gross profit and operating margins are not meaningful because the company reported no revenue. At June 30, 2017, cash and cash equivalents were $76.2 million, total current assets $78.1 million, current liabilities $7.3 million, and stockholders’ equity $73.3 million. The balance sheet reports $46,000 of long-term liabilities; it does not identify borrowings or provide a separate debt balance. For the six months, operating cash use was $21.1 million, investing cash use was $0.4 million, and financing provided $37.6 million. Accumulated deficit was $268.9 million.
Changes versus the prior comparable period
- Q2 operating expenses rose 31% year over year; R&D increased 43%, mainly from higher VTL-308 and prior-trial costs, including more enrollment and manufacturing activity, and preparation for a potential BLA.
- Q2 net loss increased from $9.5 million to $12.4 million; six-month net loss increased from $19.1 million to $25.0 million.
- Six-month operating cash use increased from $18.8 million to $21.1 million. Financing cash inflow rose from $8.8 million to $37.6 million, principally reflecting the March 2017 equity offering.
- Cash increased from $60.0 million at December 31, 2016 to $76.2 million at June 30, 2017. Common shares outstanding increased from 32.1 million to 42.2 million, primarily following the March offering.
Outlook, commentary, and risks
- As of August 2, 2017, the company reported 95 subjects enrolled in VTL-308 and 49 sites open. It expected at least 150 subjects and 55 events; top-line results were anticipated around mid-2018, most likely in the third quarter.
- Management estimated that June-end cash would fund operations through the first quarter of 2019, assuming limited BLA-related work and no significant commercial infrastructure build. This estimate is subject to enrollment, spending, regulatory, and other uncertainties.
- The company expected R&D costs for the remainder of 2017 not to increase significantly from the first half, subject to trial enrollment, and G&A costs to remain relatively consistent.
- Management stated additional capital would be needed. The company had $113.1 million remaining under its shelf registration statement, including $62.8 million available through its at-the-market facility, but no committed external funding. Further equity financing could dilute shareholders; funding may not be available on acceptable terms.
- Major risks include VTL-308 failing to demonstrate efficacy, regulators requiring another pivotal trial, enrollment delays, manufacturing and single-supplier dependencies, clinical safety concerns, and failure to obtain regulatory approval or adequate reimbursement. The prior VTI-208 Phase 3 failure makes clinical success especially uncertain.
- The company reported no material litigation known to it. Disclosure controls were assessed as effective at the reasonable-assurance level, with no material change in internal control reported for the period.
Most important facts for investors to verify
- Confirm the issuer: this document is Vital Therapies, Inc.’s 10-Q, not Immunic, Inc.’s filing.
- Check subsequent VTL-308 enrollment, event accrual, trial results, and whether regulators required additional studies.
- Assess cash burn and financing needs against the stated runway through Q1 2019, including any changes to BLA or commercialization spending.
- Review the dilutive effect of the March 2017 offering, outstanding options and warrants, and any later use of the shelf or ATM facility.
- Evaluate whether the prior Phase 3 failure, trial-design assumptions, and manufacturing and supplier risks materially affect the prospects for ELAD.